Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2017 Aug;31(4):577-587. doi: 10.1016/j.hoc.2017.04.006.

Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4-100, Seattle, WA 98104, USA. Electronic address: jradich@fredhutch.org.
2
Myeloproliferative Neoplasms Program, Leukemia Section, Memorial Sloan Kettering Cancer Center, 1275 York Avenue (Between 67th and 68th street), New York, NY 10065, USA.

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder that accounts for approximately 10% of new cases of leukemia. The introduction of tyrosine kinase inhibitors has led to a reduction in mortalities. Thus, the estimated prevalence of CML is increasing. The National Comprehensive Cancer Network and the European Leukemia Net guidelines incorporate frequent molecular monitoring of the fusion BCR-ABL transcript to ensure that patients reach and keep treatment milestones. Most patients with CML are diagnosed in the chronic phase, and approximately 10% to 30% of these patients will at some time in their course meet definition criteria of resistance to imatinib.

KEYWORDS:

BCR-ABL; Chronic myeloid leukemia; Imatinib; Molecular response; Tyrosine kinase Inhibitor

PMID:
28673389
DOI:
10.1016/j.hoc.2017.04.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center